Guangzhou Improve Med Instrument (300030) - Net Assets
Based on the latest financial reports, Guangzhou Improve Med Instrument (300030) has net assets worth CN¥677.10 Million CNY (≈ $99.08 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.02 Billion ≈ $149.71 Million USD) and total liabilities (CN¥346.01 Million ≈ $50.63 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Guangzhou Improve Med Instrument tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥677.10 Million |
| % of Total Assets | 66.18% |
| Annual Growth Rate | 20.37% |
| 5-Year Change | -36.42% |
| 10-Year Change | -31.34% |
| Growth Volatility | 141.88 |
Guangzhou Improve Med Instrument - Net Assets Trend (2006–2025)
This chart illustrates how Guangzhou Improve Med Instrument's net assets have evolved over time, based on quarterly financial data. See how many days can Guangzhou Improve Med Instrument fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Guangzhou Improve Med Instrument (2006–2025)
The table below shows the annual net assets of Guangzhou Improve Med Instrument from 2006 to 2025. For live valuation and market cap data, see 300030 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥655.10 Million ≈ $95.86 Million |
+1.74% |
| 2024-12-31 | CN¥643.86 Million ≈ $94.22 Million |
-15.54% |
| 2023-12-31 | CN¥762.33 Million ≈ $111.55 Million |
-7.10% |
| 2022-12-31 | CN¥820.61 Million ≈ $120.08 Million |
-20.36% |
| 2021-12-31 | CN¥1.03 Billion ≈ $150.78 Million |
+2.75% |
| 2020-12-31 | CN¥1.00 Billion ≈ $146.74 Million |
+19.63% |
| 2019-12-31 | CN¥838.26 Million ≈ $122.66 Million |
+2.79% |
| 2018-12-31 | CN¥815.47 Million ≈ $119.33 Million |
-15.38% |
| 2017-12-31 | CN¥963.72 Million ≈ $141.02 Million |
+1.00% |
| 2016-12-31 | CN¥954.18 Million ≈ $139.63 Million |
+2.55% |
| 2015-12-31 | CN¥930.46 Million ≈ $136.16 Million |
+18.98% |
| 2014-12-31 | CN¥782.00 Million ≈ $114.43 Million |
+1.20% |
| 2013-12-31 | CN¥772.70 Million ≈ $113.07 Million |
+12.32% |
| 2012-12-31 | CN¥687.93 Million ≈ $100.67 Million |
+6.12% |
| 2011-12-31 | CN¥648.25 Million ≈ $94.86 Million |
+9.40% |
| 2010-12-31 | CN¥592.55 Million ≈ $86.71 Million |
+5.15% |
| 2009-12-31 | CN¥563.53 Million ≈ $82.46 Million |
+615.80% |
| 2008-12-31 | CN¥78.73 Million ≈ $11.52 Million |
+35.12% |
| 2007-12-31 | CN¥58.27 Million ≈ $8.53 Million |
+201.39% |
| 2006-12-31 | CN¥19.33 Million ≈ $2.83 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangzhou Improve Med Instrument's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1738.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥757.08 Million | 122.04% |
| Total Equity | CN¥620.34 Million | 100.00% |
Guangzhou Improve Med Instrument Competitors by Market Cap
The table below lists competitors of Guangzhou Improve Med Instrument ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DocMorris AG
SW:DOCM
|
$281.88 Million |
|
Rocky Brands Inc
NASDAQ:RCKY
|
$281.90 Million |
|
Sygnia Ltd
JSE:SYG
|
$281.96 Million |
|
Forcecon Technology Co Ltd
TWO:3483
|
$282.03 Million |
|
Bank Multiarta Sentosa PT
JK:MASB
|
$281.78 Million |
|
Ive Group Ltd
AU:IGL
|
$281.77 Million |
|
Shenzhen Maxonic Auto Control
SHE:300112
|
$281.57 Million |
|
Parrot
PA:PARRO
|
$281.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangzhou Improve Med Instrument's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 606,734,458 to 620,335,334, a change of 13,600,876 (2.2%).
- Net income of 14,530,384 contributed positively to equity growth.
- Dividend payments of 5,496,454 reduced retained earnings.
- Other comprehensive income decreased equity by 53,869,765.
- Other factors increased equity by 58,436,711.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥14.53 Million | +2.34% |
| Dividends Paid | CN¥5.50 Million | -0.89% |
| Other Comprehensive Income | CN¥-53.87 Million | -8.68% |
| Other Changes | CN¥58.44 Million | +9.42% |
| Total Change | CN¥- | 2.24% |
Book Value vs Market Value Analysis
This analysis compares Guangzhou Improve Med Instrument's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.11x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 58.63x to 3.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.11 | CN¥6.23 | x |
| 2007-12-31 | CN¥0.32 | CN¥6.23 | x |
| 2008-12-31 | CN¥0.40 | CN¥6.23 | x |
| 2009-12-31 | CN¥2.67 | CN¥6.23 | x |
| 2010-12-31 | CN¥2.04 | CN¥6.23 | x |
| 2011-12-31 | CN¥2.11 | CN¥6.23 | x |
| 2012-12-31 | CN¥2.18 | CN¥6.23 | x |
| 2013-12-31 | CN¥2.37 | CN¥6.23 | x |
| 2014-12-31 | CN¥2.48 | CN¥6.23 | x |
| 2015-12-31 | CN¥3.00 | CN¥6.23 | x |
| 2016-12-31 | CN¥3.10 | CN¥6.23 | x |
| 2017-12-31 | CN¥3.42 | CN¥6.23 | x |
| 2018-12-31 | CN¥2.61 | CN¥6.23 | x |
| 2019-12-31 | CN¥2.57 | CN¥6.23 | x |
| 2020-12-31 | CN¥3.26 | CN¥6.23 | x |
| 2021-12-31 | CN¥3.23 | CN¥6.23 | x |
| 2022-12-31 | CN¥2.53 | CN¥6.23 | x |
| 2023-12-31 | CN¥2.29 | CN¥6.23 | x |
| 2024-12-31 | CN¥1.96 | CN¥6.23 | x |
| 2025-12-31 | CN¥2.01 | CN¥6.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangzhou Improve Med Instrument utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.99%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.66x
- Recent ROE (2.34%) is below the historical average (4.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 43.16% | 18.91% | 1.10x | 2.07x | CN¥6.41 Million |
| 2007 | 22.64% | 18.24% | 0.98x | 1.27x | CN¥7.36 Million |
| 2008 | 25.99% | 19.78% | 0.73x | 1.80x | CN¥12.59 Million |
| 2009 | 4.77% | 19.11% | 0.21x | 1.17x | CN¥-29.45 Million |
| 2010 | 4.90% | 17.50% | 0.25x | 1.10x | CN¥-30.23 Million |
| 2011 | 5.75% | 14.29% | 0.35x | 1.15x | CN¥-26.41 Million |
| 2012 | 5.80% | 12.32% | 0.40x | 1.19x | CN¥-27.13 Million |
| 2013 | 6.74% | 11.62% | 0.45x | 1.29x | CN¥-22.31 Million |
| 2014 | 7.27% | 11.49% | 0.45x | 1.40x | CN¥-19.94 Million |
| 2015 | 4.33% | 7.30% | 0.38x | 1.56x | CN¥-52.23 Million |
| 2016 | 3.23% | 5.89% | 0.35x | 1.56x | CN¥-63.96 Million |
| 2017 | 1.17% | 2.03% | 0.31x | 1.83x | CN¥-84.33 Million |
| 2018 | -16.87% | -24.87% | 0.36x | 1.86x | CN¥-217.88 Million |
| 2019 | 3.11% | 4.53% | 0.38x | 1.80x | CN¥-57.57 Million |
| 2020 | 16.26% | 17.68% | 0.53x | 1.75x | CN¥62.54 Million |
| 2021 | 1.86% | 2.32% | 0.44x | 1.82x | CN¥-81.45 Million |
| 2022 | -25.28% | -27.90% | 0.46x | 1.99x | CN¥-276.73 Million |
| 2023 | -8.74% | -9.80% | 0.45x | 1.97x | CN¥-135.51 Million |
| 2024 | -19.43% | -20.28% | 0.47x | 2.05x | CN¥-178.58 Million |
| 2025 | 2.34% | 2.99% | 0.47x | 1.66x | CN¥-47.50 Million |
Industry Comparison
This section compares Guangzhou Improve Med Instrument's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,292,571,972
- Average return on equity (ROE) among peers: 8.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangzhou Improve Med Instrument (300030) | CN¥677.10 Million | 43.16% | 0.51x | $281.87 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $1.79 Billion | 0.80% | 1.04x | $441.93 Million |
| Blue Sail Medical Co Ltd (002382) | $916.68 Million | 3.17% | 0.43x | $805.03 Million |
| Andon Health Co Ltd (002432) | $775.55 Million | 2.68% | 0.08x | $4.55 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $1.32 Billion | 17.23% | 1.19x | $827.51 Million |
| QITIAN Technology Group Co Ltd (300061) | $79.12 Million | 18.52% | 1.47x | $737.70 Million |
| Shanghai Tofflon Science Tech (300171) | $3.24 Billion | 4.50% | 0.61x | $1.28 Billion |
| Truking Technology Ltd (300358) | $2.41 Billion | 1.94% | 0.86x | $847.59 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $845.23 Million | 13.68% | 0.47x | $744.87 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $247.00 Million | 14.43% | 0.08x | $1.33 Billion |
About Guangzhou Improve Med Instrument
Improve Medical Instruments Co., Ltd. engages in the provision of relevant technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. It provides clinical laboratory products comprising feces and thrombosis viscoelastic analysis systems; and automatic biosafety decappers; and Q-VELOX, an intelligent molecular diagnostic workstation. The company… Read more